SURROZEN INC
SRZNNASDAQTrading Snapshot
- Day Range
- $27.73 – $29.51
- 52-Week Range
- $11.39 – $37.83
- Volume (shares)
- 231,860
- Avg Volume (shares)
- —
- Shares Outstanding
- 17.8M
- Next Earnings
- 2026-11-06
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $5M
- P/E Ratio
- —
- P/S Ratio
- 30.1x
- EPS (TTM)
- $-35.79
- Dividend Yield
- —
- Dilution (1yr)
- +178.9%
SURROZEN INC
SRZN
StockOtter · stockotter.spaceAbout SURROZEN INC
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to ad
Head to Head Review: Surrozen (NASDAQ:SRZN) and Prelude Therapeutics (NASDAQ:PRLD)
Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and Surrozen (NASDAQ: SRZN - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on t
Surrozen (NASDAQ:SRZN) & Whitehawk Therapeutics (NASDAQ:WHWK) Financial Comparison
Surrozen (NASDAQ: SRZN - Get Free Report) and Whitehawk Therapeutics (NASDAQ: WHWK - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on th
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds SOUTH SAN FR
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy
Surrozen Inc. (NASDAQ:SRZN) skyrocketed on Thursday after the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration to evaluate SZN-8141 for treating diabetic macular edema.
Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript